Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 38, Issue 3, Pages 531-539
Publisher
Springer Nature
Online
2010-11-11
DOI
10.1007/s00259-010-1646-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
- (2010) E C Dijkers et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
- (2010) J. Löfblom et al. FEBS LETTERS
- Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
- (2010) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass
- (2010) Irina Velikyan et al. NUCLEAR MEDICINE AND BIOLOGY
- Quantitative analysis of PET studies
- (2010) Wolfgang A. Weber RADIOTHERAPY AND ONCOLOGY
- Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount
- (2009) Vladimir Tolmachev et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules
- (2009) G. Kramer-Marek et al. JOURNAL OF NUCLEAR MEDICINE
- Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine
- (2009) S. Ahlgren et al. JOURNAL OF NUCLEAR MEDICINE
- HER-2/neu expression in primary and metastatic breast cancer
- (2008) Elyse E. Lower et al. BREAST CANCER RESEARCH AND TREATMENT
- Slow Internalization of Anti-HER2 Synthetic Affibody Monomer 111In-DOTA-ZHER2:342-pep2 : Implications for Development of Labeled Tracers
- (2008) Helena Wållberg et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold
- (2008) Per-Åke Nygren FEBS Journal
- Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy
- (2008) N. Pandit-Taskar et al. JOURNAL OF NUCLEAR MEDICINE
- Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules
- (2008) Z. Cheng et al. JOURNAL OF NUCLEAR MEDICINE
- The importance of high specific radioactivity in the performance of 68Ga-labeled peptide
- (2008) Irina Velikyan et al. NUCLEAR MEDICINE AND BIOLOGY
- Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer
- (2008) David A Cameron et al. Nature clinical practice. Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started